Classification of Beta-Blockers
This drug class is traditionally categorized by receptor selectivity:
- Cardioselective (\(\beta_1\)-selective blockers): atenolol, betaxolol, bisoprolol, nebivolol, metoprolol, talinolol.
- Non-selective (\(\beta_1\)- and \(\beta_2\)-blockers): the prototype agent propranolol, as well as nadolol, timolol, pindolol, and oxprenolol.
Additionally, agents may differ in mechanism of action, duration of effect, and routes of administration, though selectivity primarily determines their clinical and safety profile.
Pharmacodynamics: Cardiac and Renal Effects
Key therapeutic effects stem from the blockade of \(\beta_1\)-adrenergic receptors located predominantly in the heart and kidneys.
Direct Cardiac Effects:
- Negative inotropic effect: reduction in myocardial contractility.
- Negative chronotropic effect: decreased heart rate via suppression of sinus node automaticity.
- Negative dromotropic effect: depression of atrioventricular (AV) conduction.
- Decreased automaticity of ectopic pacemakers (AV node and Purkinje fibers).
Systemic consequences of these cardiac effects include a reduction in cardiac output and a substantial decrease in myocardial oxygen demand, which is critical in managing ischemic heart disease.
Renal Effects: Blockade of receptors on renal juxtaglomerular cells leads to an approximately 60% reduction in renin secretion. This impairs angiotensin II formation, eliminating its potent vasoconstrictor action and contributing significantly to a sustained antihypertensive effect.
Mechanisms of the Antihypertensive Effect
Blood pressure reduction during chronic beta-blocker therapy is mediated by multiple mechanisms:
- Cardiac component: reduction in cardiac output primarily lowers systolic pressure.
- Renal mechanism: suppression of the renin-angiotensin-aldosterone system (RAAS) eliminates vascular spasm, reducing total peripheral resistance (TPR) and diastolic pressure.
- Baroreflex resetting: agents increase the sensitivity of aortic arch and carotid sinus baroreceptors (depressor reflexes typically blunted in hypertension).
- Presynaptic inhibition: blockade of \(\beta_2\)-receptors on sympathetic nerve terminals decreases norepinephrine release into the synaptic cleft.
- Additional properties: propranolol possesses central inhibitory actions, while nebivolol stimulates endothelial nitric oxide (NO) production, causing additional vasodilation.
Vascular Tone Dynamics During Therapy
Administration of non-selective blockers is accompanied by biphasic changes in vascular tone:
- Initial reaction (paradoxical tone increase): early in treatment, decreased cardiac output reduces baroreceptor stimulation, triggering a compensatory activation of the sympathetic nervous system. Because vasodilatory \(\beta_2\)-receptors are blocked, circulating epinephrine stimulates only \(\alpha_1\)-receptors, causing vasoconstriction.
- Delayed effect: after 1–2 weeks of regular administration, blood vessels dilate, TPR drops, and a sustained reduction in blood pressure is established.
Effects of \(\beta_2\)-Receptor Blockade and Metabolism
Non-selective blockade of smooth muscle \(\beta_2\)-receptors causes several extra-cardiac effects often responsible for adverse reactions. These include constriction of blood vessels (in skeletal muscle and the coronary bed) and increased bronchial tone with a risk of bronchospasm. Myometrial tone and contractility also increase, alongside enhanced gastrointestinal motility.
Metabolic Impact:
- Carbohydrate metabolism: hepatic and skeletal muscle glycogenolysis is suppressed, blunting the hyperglycemic response to epinephrine. Blood glucose levels drop while insulin secretion by pancreatic \(\beta\)-cells is inhibited.
- Lipid metabolism: blockade of adipocyte receptors inhibits lipolysis, lowering free fatty acid levels in the blood.